Luoxin Biotechnology Co. Ltd., of Shanghai, and Innovent Biologics Inc., of Hong Kong, said they selected Oracle Argus to help them comply with new drug safety regulations and reporting in China. Mundipharma International Co. Ltd., of Cambridge, U.K., said it extended its partnership with Kolon Life Science, a subsidiary of South Korean conglomerate Kolon Group, to market Invossa-K in Saudi Arabia and the United Arab Emirates. Financial terms were not disclosed.